In 2011 Crizotinib received FDA approval for the treatment of ALK-positive NSCLC. Due to large diversity in clinical course of these patients, baseline genomic profiling at diagnostic biopsy was performed to find possible correlations with clinical features. We performed a retrospective analysis of 28 consecutive patients receiving Crizotinib for metastatic, immunohistochemistry (IHC)- and fluorescens in-situ hybridization (FISH)-determined ALK-positive NSCLC, between September 2011 and DATE. Clinical data were collected by chart review. DNA/RNA genomic profile were performed using the patients’ biopsy at the time of diagnosis or at initiation of therapy using targeted next-generation sequencing (NGS) Oncomine™ Focus (ThermoFisher Scientific) and Archer® Solid Tumor (ArcherDx) assays. Baseline clinical features and genetic information were correlated with overall survival and progression free survival. Although this small cohort does not allow to draw unambiguous conclusions, it does i..... READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.2196
Authors: L. Melchior, E. Santoni Rugiu, J. Sørensen, J. Bjerregaard, E. Urbanska
